newsfilter
← Latest News
GlobeNewswire·

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 i